MedX Health has partnered with Central Health, the second largest health authority in Newfoundland and Labrador, to introduce DermSecure® Screening Platform Services to 176 communities across the province.
MISSISSAUGA, Ontario–(BUSINESS WIRE)–$MDX #SkinCancer—MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX), a global leader in teledermatology, and Central Health are pleased to announce the launch of MedX’s DermSecure® skin screening services in Newfoundland and Labrador.
The paid pilot program, which will span 60 days, will see MedX implement its training program for nurses and supervisors to easily integrate the DermSecure® Screening Platform into the Central Health patient service offerings. Additionally, the Company will provide training for dermatologists who will be reading the scans and establishing the protocols in conjunction with mobile services already provided by Newfoundland’s health care system to improve access to dermatological services in remote communities across the province. Upon the successful completion of the pilot, the MedX DermSecure® Screening Platform will be made available to Central Health’s patients across Newfoundland and Labrador.
“The paid pilot further verifies that our DermSecure platform meets all the necessary privacy and security requirements of a Canadian Provincial Government health care system,” stated MedX Director of North American Sales, Paul Ziemer. “The challenges for physicians to effectively deliver care across this geography have been instrumental in Newfoundland and Labrador’s prioritization and establishment of one of Canada’s most robust telemedicine programs. The DermSecure platform and the images it provides for the doctors and dermatologists in the province will fit seamlessly into their telemedicine program and get the doctors and patients the information they need quickly and efficiently.”
Central Health is the second largest health authority in Newfoundland and Labrador, serving approximately 93,000 people (18 per cent of the province’s population) living in 176 communities. With a geographical area encompassing more than half the total land mass of the island, the Central Health region extends from Charlottetown in the east, Fogo Island in the north, Harbour Breton in the south, to Baie Verte in the west. Central Health provides a variety of primary, secondary, long-term care, community health, and other enhanced secondary services through:
- 2 Regional Referral Centres
- 9 Health Centres
11 Long-term Care facilities (seven co-located in Health Centres)
- 2 new Long-term Care facilities (Gander and Grand Falls-Windsor) and a protective care unit expansion at Dr. Hugh Twomey Health Centre in Botwood
- 24 Community Health Centres
- 2 Residential Treatment Centres
- 1 Regional Office
Implementing MedX’s DermSecure® solution will serve to relieve the pressure facing family physicians and dermatologists in the Newfoundland and Labrador region, allowing them to alleviate the stress of melanoma screenings for their roster of patients in their practices quickly and efficiently. It will also greatly speed up the management of non-life threatening but potentially difficult cases such as inflammatory conditions like acne, psoriasis and eczema.
Naman Demaghlatrous, CEO of MedX Health said, “We are delighted to bring our DermSecure screening solution to the residents of Newfoundland and Labrador. MedX would like to thank Dr. Ian Landells, lead dermatologist for this pilot, the team at Central Health, and Ashley Dinn, Program Manager for the Virtual Care and Registry Integrity Unit at the Newfoundland and Labrador Centre for Health Information, for all of their hard work in driving this project to success.”
Teledermatology is a subspecialty of dermatology that offers safe and effective virtual care – patient screening and assessment – eliminating the need for in-person appointments with a dermatologist. MedX is a global leader in teledermatology through its high-definition image capture technology, SIAscopy®, and its secure, cloud-based patient management system, DermSecure®, which transmits and stores patient data throughout the assessment process. MedX’s SIAscopy® is the only technology globally that captures five high-resolution images of suspicious moles, lesions and skin conditions, including four spectrophotometric images 2mm below the skin’s surface. This technology provides detailed patient scans for virtual dermatological assessment by a certified dermatologist within 72 hours.
MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. Visit www.medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
Bill Mitoulas, Investor Relations
MedX Health Corp.